Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy

NCT06317298 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma, Clear Cell, Somatic

Interventions

DRUG: Fruquintinib and Everolimus

Sponsor

Peking University First Hospital